NBIX vs. ACGL
NBIX (Neurocrine Biosciences, Inc.) and ACGL (Arch Capital Group Ltd.) are both stocks. NBIX operates in Drug Manufacturers - Specialty & Generic (Healthcare), while ACGL operates in Insurance - Diversified (Financial Services). Over the past 10 years, NBIX returned 12.71%/yr vs 15.70%/yr for ACGL. Their 0.17 correlation means their historical movements had little consistent relationship.
Performance
NBIX vs. ACGL - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NBIX achieves a 17.61% return, which is significantly higher than ACGL's 4.81% return. Over the past 10 years, NBIX has underperformed ACGL with an annualized return of 12.71%, while ACGL has yielded a comparatively higher 15.70% annualized return.
NBIX
- 1D
- -10.08%
- 1M
- -0.58%
- 6M
- 22.59%
- YTD
- 17.61%
- 1Y
- 30.08%
- 3Y*
- 17.27%
- 5Y*
- 12.34%
- 10Y*
- 12.71%
- ALL TIME*
- 9.11%
ACGL
- 1D
- -0.60%
- 1M
- 2.01%
- 6M
- 4.68%
- YTD
- 4.81%
- 1Y
- 16.81%
- 3Y*
- 11.10%
- 5Y*
- 22.07%
- 10Y*
- 15.70%
- ALL TIME*
- 13.23%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $213.28M | $189.90M | $217.00M | |
| $278.93M | $232.17M | $211.02M |
NBIX vs. ACGL - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences, Inc. | 17.61% | 3.90% | 3.60% | 10.31% | 40.24% | -11.14% | -10.83% | 50.53% | -7.96% | 100.49% |
ACGL Arch Capital Group Ltd. | 4.81% | 3.87% | 30.76% | 18.30% | 41.24% | 23.23% | -15.90% | 60.52% | -11.69% | 5.19% |
Correlation
The correlation between NBIX and ACGL is 0.04, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.04 |
Correlation (3Y) Balances recent behavior with more history. | 0.10 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.15 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.16 |
Correlation (All Time) Calculated using the full available price history since May 23, 1996 | 0.17 |
The correlation between NBIX and ACGL shifts across timeframes, from 0.04 (1 year) to 0.17 (all time), reflecting how their relationship changes across market environments.
Fundamentals
NBIX:
$16.77B
ACGL:
$35.12B
NBIX:
$6.84
ACGL:
$12.85
NBIX:
24.39
ACGL:
7.82
NBIX:
0.48
ACGL:
0.18
NBIX:
5.10
ACGL:
1.91
NBIX:
4.35
ACGL:
1.51
NBIX:
$3.37B
ACGL:
$19.20B
NBIX:
$3.31B
ACGL:
$6.56B
NBIX:
$940.50M
ACGL:
$5.60B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NBIX vs. ACGL — Risk / Return Rank
NBIX
ACGL
NBIX vs. ACGL - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and Arch Capital Group Ltd. (ACGL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NBIX | ACGL | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.12 | ||
| Sortino ratioReturn per unit of downside risk | +0.20 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 1.15 | +0.04 |
| Calmar ratioReturn relative to maximum drawdown | 1.45 | 1.20 | +0.25 |
| Martin ratioReturn relative to average drawdown | 3.18 | 3.11 | +0.07 |
Loading charts...
Drawdowns
NBIX vs. ACGL - Drawdown Comparison
The maximum NBIX drawdown since its inception was -97.21%, which is greater than ACGL's maximum drawdown of -54.70%. Use the drawdown chart below to compare losses from any high point for NBIX and ACGL.
Loading charts...
Drawdown Indicators
| NBIX | ACGL | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.21% | -54.70% | -42.51% |
Max Drawdown (1Y)Largest decline over 1 year | -20.90% | -14.08% | -6.82% |
Max Drawdown (3Y)Largest decline over 3 years | -42.89% | -22.43% | -20.46% |
Max Drawdown (5Y)Largest decline over 5 years | -42.89% | -22.43% | -20.46% |
Max Drawdown (10Y)Largest decline over 10 years | -46.39% | -53.84% | +7.45% |
Current DrawdownCurrent decline from peak | -10.08% | -7.96% | -2.12% |
Average DrawdownAverage peak-to-trough decline | -43.66% | -11.71% | -31.95% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.47% | 5.41% | +4.06% |
Volatility
NBIX vs. ACGL - Volatility Comparison
Neurocrine Biosciences, Inc. (NBIX) has a higher volatility of 14.12% compared to Arch Capital Group Ltd. (ACGL) at 8.78%. This indicates that NBIX's price experiences larger fluctuations and is considered to be riskier than ACGL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NBIX | ACGL | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.12% | 8.78% | +5.34% |
Volatility (6M)Calculated over the trailing 6-month period | 26.01% | 16.73% | +9.28% |
Volatility (1Y)Calculated over the trailing 1-year period | 33.74% | 21.43% | +12.31% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.17% | 24.61% | +8.56% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 39.18% | 27.63% | +11.55% |
Dividends
NBIX vs. ACGL - Dividend Comparison
Neither NBIX nor ACGL has paid dividends to shareholders.
| Position | TTM | 2025 | 2024 |
|---|---|---|---|
ACGL Arch Capital Group Ltd. | 0.00% | 0.00% | 5.41% |
NBIX Neurocrine Biosciences, Inc. | 0.00% | 0.00% | 0.00% |
Financials
NBIX vs. ACGL - Financials Comparison
This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and Arch Capital Group Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NBIX vs. ACGL - Profitability Comparison
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Neurocrine Biosciences, Inc. reported a gross profit of 935.80M and revenue of 959.00M. Therefore, the gross margin over that period was 97.6%.
ACGL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Arch Capital Group Ltd. reported a gross profit of -30.00M and revenue of 4.47B. Therefore, the gross margin over that period was -0.7%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Neurocrine Biosciences, Inc. reported an operating income of 151.50M and revenue of 959.00M, resulting in an operating margin of 15.8%.
ACGL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Arch Capital Group Ltd. reported an operating income of 46.00M and revenue of 4.47B, resulting in an operating margin of 1.0%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Neurocrine Biosciences, Inc. reported a net income of 144.40M and revenue of 959.00M, resulting in a net margin of 15.1%.
ACGL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Arch Capital Group Ltd. reported a net income of 1.06B and revenue of 4.47B, resulting in a net margin of 23.6%.
Frequently Asked Questions
NBIX and ACGL have a correlation of 0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NBIX has higher volatility (14.12%) compared to ACGL (8.78%). In terms of maximum drawdown, NBIX dropped -97.21% vs ACGL's -54.70%.
NBIX currently has the higher Sharpe Ratio (0.91 vs 0.79), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NBIX and ACGL
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer